385 related articles for article (PubMed ID: 26826721)
41. Definitive Radiotherapy Following Induction Chemotherapy for Hypopharyngeal Cancer: Selecting Candidates for Organ-Preserving Treatment Based on the Response to Induction Chemotherapy.
Yanagi T; Shibamoto Y; Ogino H; Baba F; Murai T; Nagai A; Miyakawa A; Sugie C
Kurume Med J; 2016; 62(1-2):1-8. PubMed ID: 26935442
[TBL] [Abstract][Full Text] [Related]
42. [Prognostic factors affecting results of comprehensive treatment of hypopharyngeal carcinoma].
Xu W; Lyu Z; Yang Z; Zou J; Cao H
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2014 Jul; 49(7):533-8. PubMed ID: 25257265
[TBL] [Abstract][Full Text] [Related]
43. Locoregional Control and Toxicity in Head and Neck Carcinoma Patients following Helical Tomotherapy-Delivered Intensity-Modulated Radiation Therapy Compared with 3D-CRT Data.
Santa Cruz O; Tsoutsou P; Castella C; Khanfir K; Anchisi S; Bouayed S; Matzinger O; Ozsahin M
Oncology; 2018; 95(2):61-68. PubMed ID: 29895020
[TBL] [Abstract][Full Text] [Related]
44. Safety and efficacy of concurrent carboplatin plus radiotherapy for locally advanced head and neck cancer patients ineligible for treatment with cisplatin.
Hamauchi S; Yokota T; Onozawa Y; Ogawa H; Onoe T; Kamijo T; Iida Y; Nishimura T; Onitsuka T; Yasui H
Jpn J Clin Oncol; 2015 Dec; 45(12):1116-21. PubMed ID: 26423341
[TBL] [Abstract][Full Text] [Related]
45. Impact of concomitant chemoradiation on survival for patients with T1-2N1 head and neck cancer.
Zumsteg ZS; Kim S; David JM; Yoshida EJ; Tighiouart M; Shiao SL; Scher K; Mita A; Sherman EJ; Lee NY; Ho AS
Cancer; 2017 May; 123(9):1555-1565. PubMed ID: 28001302
[TBL] [Abstract][Full Text] [Related]
46. Laryngeal preservation in advanced piriform sinus squamous cell carcinomas using superselective intra-arterial chemoradiation therapy with three agents.
Furusaka T; Matsuda A; Tanaka A; Matsuda H; Ikeda M
Acta Otolaryngol; 2013 Mar; 133(3):318-26. PubMed ID: 23153059
[TBL] [Abstract][Full Text] [Related]
47. Utility of algorithm-based chemoradioselection in the treatment for advanced hypopharyngeal carcinoma.
Masuda M; Matsuo M; Aso T; Kiyohara H; Rikimaru F; Kunitake N; Higaki Y
Head Neck; 2015 Sep; 37(9):1290-6. PubMed ID: 24816950
[TBL] [Abstract][Full Text] [Related]
48. Hyperfractionated accelerated radiation therapy (HART) of 70.6 Gy with concurrent 5-FU/Mitomycin C is superior to HART of 77.6 Gy alone in locally advanced head and neck cancer: long-term results of the ARO 95-06 randomized phase III trial.
Budach V; Stromberger C; Poettgen C; Baumann M; Budach W; Grabenbauer G; Marnitz S; Olze H; Wernecke KD; Ghadjar P
Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):916-24. PubMed ID: 25670541
[TBL] [Abstract][Full Text] [Related]
49. Treatment results of alternating chemoradiotherapy with early assessment for advanced laryngeal cancer: A multi-institutional phase II study.
Nakata Y; Ijichi K; Hanai N; Nishikawa D; Suzuki H; Hirakawa H; Kodaira T; Fujimoto Y; Fujii T; Miyazaki T; Shimizu T; Hasegawa Y
Auris Nasus Larynx; 2017 Feb; 44(1):104-110. PubMed ID: 27435048
[TBL] [Abstract][Full Text] [Related]
50. Impact of the early detection of esophageal neoplasms in hypopharyngeal cancer patients treated with concurrent chemoradiotherapy.
Watanabe S; Ogino I; Inayama Y; Sugiura M; Sakuma Y; Kokawa A; Kunisaki C; Inoue T
Asia Pac J Clin Oncol; 2017 Apr; 13(2):e3-e10. PubMed ID: 25359448
[TBL] [Abstract][Full Text] [Related]
51. Prospective Study of Cetuximab, Carboplatin, and Radiation Therapy for Patients With Locally Advanced Head and Neck Squamous Cell Cancer Unfit for Cisplatin.
Corry J; Bressel M; Fua T; Herschtal A; Solomon B; Porceddu SV; Wratten C; Rischin D
Int J Radiat Oncol Biol Phys; 2017 Jul; 98(4):948-954. PubMed ID: 28483336
[TBL] [Abstract][Full Text] [Related]
52. Definitive Chemoradiotherapy Versus Surgery Followed by Adjuvant Radiotherapy in Resectable Stage III/IV Hypopharyngeal Cancer.
Kim JW; Kim MS; Kim SH; Kim JH; Lee CG; Kim GE; Keum KC
Cancer Res Treat; 2016 Jan; 48(1):45-53. PubMed ID: 25779363
[TBL] [Abstract][Full Text] [Related]
53. Intensity modulated radiotherapy with concurrent chemotherapy for larynx preservation of advanced resectable hypopharyngeal cancer.
Huang WY; Jen YM; Chen CM; Su YF; Lin CS; Lin YS; Chang YN; Chao HL; Lin KT; Chang LP
Radiat Oncol; 2010 May; 5():37. PubMed ID: 20470428
[TBL] [Abstract][Full Text] [Related]
54. Value of intensity-modulated radiotherapy in Stage IV head-and-neck squamous cell carcinoma.
Dirix P; Nuyts S
Int J Radiat Oncol Biol Phys; 2010 Dec; 78(5):1373-80. PubMed ID: 20362402
[TBL] [Abstract][Full Text] [Related]
55. Management of advanced hypopharyngeal and laryngeal cancer with and without cartilage invasion.
Scherl C; Mantsopoulos K; Semrau S; Fietkau R; Kapsreiter M; Koch M; Traxdorf M; Grundtner P; Iro H
Auris Nasus Larynx; 2017 Jun; 44(3):333-339. PubMed ID: 27569289
[TBL] [Abstract][Full Text] [Related]
56. Outcomes following chemoradiotherapy for N3 head and neck squamous cell carcinoma without a planned neck dissection.
Karakaya E; Yetmen O; Oksuz DC; Dyker KE; Coyle C; Sen M; Prestwich RJ
Oral Oncol; 2013 Jan; 49(1):55-9. PubMed ID: 22858313
[TBL] [Abstract][Full Text] [Related]
57. Outcomes of postoperative simultaneous modulated accelerated radiotherapy for head-and-neck squamous cell carcinoma.
Moon SH; Jung YS; Ryu JS; Choi SW; Park JY; Yun T; Lee SH; Cho KH
Int J Radiat Oncol Biol Phys; 2011 Sep; 81(1):140-9. PubMed ID: 20732767
[TBL] [Abstract][Full Text] [Related]
58. Treatment results and prognostic factors for advanced squamous cell carcinoma of the hypopharynx treated with concurrent chemoradiotherapy.
Taguchi T; Nishimura G; Takahashi M; Komatsu M; Sano D; Sakuma N; Yabuki K; Arai Y; Takahashi H; Hata M; Koike I; Oridate N
Cancer Chemother Pharmacol; 2014 Jun; 73(6):1147-54. PubMed ID: 24658628
[TBL] [Abstract][Full Text] [Related]
59. Induction Toripalimab and Chemotherapy for Organ Preservation in Locally Advanced Laryngeal and Hypopharyngeal Cancer: A Single-Arm Phase II Clinical Trial.
Ou X; Zhai R; Wei W; Chen J; Ou D; Liao T; Xu T; Zhu Y; Wang Y; Huang S; Shi R; Wu B; Chen T; Li Y; Yang Z; Zhou C; Liu Y; Jiang Z; Zeng M; Liu X; Ji D; Ying H; Zhang Z; Hu C; Lu X; Ji Q; He X; Wang Y
Clin Cancer Res; 2024 Jan; 30(2):344-355. PubMed ID: 37955629
[TBL] [Abstract][Full Text] [Related]
60. Concurrent erlotinib and radiotherapy for chemoradiotherapy-intolerant esophageal squamous cell carcinoma patients: results of a pilot study.
Zhai Y; Hui Z; Wang J; Zou S; Liang J; Wang X; Lv J; Chen B; Zhu H; Wang L
Dis Esophagus; 2013 Jul; 26(5):503-9. PubMed ID: 22862289
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
